Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys

Bone

Volumn 65, Issue , 2014, Pages 1-8

  Ochi, Yasuo ^a   Yamada, Hiroyuki ^a   Mori, Hiroshi ^a   Nakanishi, Yasutomo ^a   Nishikawa, Satoshi ^a   Kayasuga, Ryoji ^a   Kawada, Naoki ^a   Kunishige, Akiko ^a   Hashimoto, Yasuaki ^a   Tanaka, Makoto ^a   Sugitani, Masafumi ^a   Kawabata, Kazuhito ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Bone metabolism; Bone mineral density; Bone strength; CATHEPSIN K; ONO 5334

Indexed keywords

ALENDRONIC ACID; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K INHIBITOR; N [3 [2 (3,4 DIMETHYL 1,3 THIAZOLIDIN 2 YLIDENE)HYDRAZINO] 2,3 DIOXO 1 (TETRAHYDRO 2H PYRAN 4 YL)PROPYL]CYCLOHEPTANECARBOXAMIDE; ONO 5334; OSTEOCALCIN; UNCLASSIFIED DRUG; CATHEPSIN K; CYSTEINE PROTEINASE INHIBITOR; ONO-5334; THIAZOLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE METABOLISM; BONE STRENGTH; BONE STRUCTURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; MACACA FASCICULARIS; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE; DRUG EFFECTS; METABOLISM; OVARIECTOMY; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; ULTRASTRUCTURE;

ABSORPTIOMETRY, PHOTON; ANIMALS; BONE AND BONES; CATHEPSIN K; CYSTEINE PROTEINASE INHIBITORS; FEMALE; MACACA FASCICULARIS; OVARIECTOMY; THIAZOLIDINES;

EID: 84900408245     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.04.023     Document Type: Article

References (33)

1. Russell R.G., Smith R., Preston C., Walton R.J., Woods C.G. Diphosphonates in Paget's disease. Lancet 1974, 1:894-898.
2. Felsenberg D., Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 2005, 27:1-11.
3. Garnero P., Delmas P.D. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 2004, 4:50-63.
4. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 1996, 348:1535-1541.
5. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
6. Chesnut I.C., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
7. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA 1999, 282:1344-1352.
8. Visekruna M., Wilson D., McKiernan F.E. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008, 93:2948-2952.
9. Gelb B.D., Shi G.P., Chapman H.A., Desnick R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996, 273:1236-1238.
10. Gowen M., Lazner F., Dodds R., Kapadia R., Feild J., Tavaria M., et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999, 14:1654-1663.
11. McQueney M.S., Feild J., Hanning C.R., Brun K., Ramachandran K., Connor J., et al. Cynomolgus monkey (Macaca fascicularis) cathepsin K: cloning, expression, purification, and activation. Protein Expr Purif 1998, 14:387-394.
12. Nishi Y., Atley L., Eyre D.E., Edelson J.G., Superti-Furga A., Yasuda T., et al. Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res 1999, 14:1902-1908.
13. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296:235-242.
14. Rizzoli R., Greenspan S.L., Bone G., Schnitzer T.J., Watts N.B., Adami S., et al. Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002, 17:1988-1996.
15. Rosen C.J., Hochberg M.C., Bonnick S.L., McClung M., Miller P., Broy S., et al. Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005, 20:141-151.
16. Ochi Y., Yamada H., Mori H., Nakanishi Y., Nishikawa S., Kayasuga R., et al. Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism. Bone 2011, 49:1351-1356.
17. Hiyaoka A., Yoshida T., Cho F., Yoshikawa Y. Age-related changes in bone mineral density, mean width and area of the lumbar vertebrae in male African green monkeys (Cercopithecus aethiops). Jikken Dobutsu 1994, 43:235-241.
18. Itoh F., Kojima M., Furihata-Komatsu H., Aoyagi S., Kusama H., Komatsu H., et al. Reductions in bone mass, structure, and strength in axial and appendicular skeletons associated with increased turnover after ovariectomy in mature cynomolgus monkeys and preventive effects of clodronate. J Bone Miner Res 2002, 17:534-543.
19. Jerome C.P., Johnson C.S., Vafai H.T., Kaplan K.C., Bailey J., Capwell B., et al. Effect of treatment for 6months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 1999, 25:301-309.
20. Jerome C., Missbach M., Gamse R. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int 2011, 22:3001-3011.
21. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 1987, 2:595-610.
22. Chappard D., Basle M.F., Legrand E., Audran M. New laboratory tools in the assessment of bone quality. Osteoporos Int 2011, 22:2225-2240.
23. Lundon K., Grynpas M. The long-term effect of ovariectomy on the quality and quantity of cortical bone in the young cynomolgus monkey: a comparison of density fractionation and histomorphometric techniques. Bone 1993, 14:389-395.
24. Smith S.Y., Recker R.R., Hannan M., Muller R., Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003, 32:45-55.
25. Mori H., Tanaka M., Kayasuga R., Masuda T., Ochi Y., Yamada H., et al. Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. Bone 2008, 43:840-848.
26. Ochi Y., Yamada H., Mori H., Kawada N., Kayasuga R., Nakanishi Y., et al. ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats. J Bone Miner Metab 2013, (Electronic publication ahead of print).
27. Ascenzi A., Bonucci E. The compressive properties of single osteons. Anat Rec 1968, 161:377-391.
28. Masarachia P.J., Pennypacker B.L., Pickarski M., Scott K.R., Wesolowski G.A., Smith S.Y., et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 2012, 27:509-523.
29. Jerome C., Missbach M., Gamse R. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int 2012, 23:339-349.
30. Martin R.M., Correa P.H. Bone quality and osteoporosis therapy. Arq Bras Endocrinol Metabol 2010, 54:186-199.
31. Matsuo K., Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys 2008, 473:201-209.
32. Rogers M.J., Crockett J.C., Coxon F.P., Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011, 49:34-41.
33. Rodan G.A.R.L., Bilezikian J.P. Pathophysiology of osteoporosis. Principles of bone biology 1996, 979-990. Academic Press, New York. 2nd ed. J.P.R.L. Bilezikian, G.A. Rodan (Eds.).